iPHASE Technologies

iPHASE Technologies is an Australian medical technology company that specializes in the development and manufacture of automated radiopharmaceutical synthesis and dispensing systems. The company provides advanced solutions for the production of PET and SPECT tracers, which are essential for molecular imaging and targeted radionuclide therapy. Their flagship products, including the Multi-Syn synthesis module, allow for the automated production of a wide range of radiopharmaceuticals using isotopes such as Fluorine-18, Carbon-11, and Gallium-68. iPHASE serves a global clientele comprising hospitals, research institutions, and commercial radiopharmacies. By streamlining complex radiochemistry processes, the company supports the advancement of precision medicine and diagnostic accuracy in oncology, neurology, and cardiology. Their systems are designed to meet stringent regulatory standards, ensuring high reliability and safety in the production of radioactive diagnostic agents.